LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

LLY

759.22

+1.45%↑

JNJ

177.16

+0.11%↑

ABBV

217.73

-0.06%↓

UNH

341.3

-1.41%↓

AZN

77.54

-0.28%↓

Search

Immunocore Holdings PLC ADR

Slēgts

33.62 -1.12

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

33.6

Max

34.34

Galvenie mērījumi

By Trading Economics

Ienākumi

-15M

-10M

Pārdošana

4.1M

98M

Peļņas marža

-10.514

Darbinieki

493

EBITDA

-11M

-15M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+71.73% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 4. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

100M

1.7B

Iepriekšējā atvēršanas cena

34.74

Iepriekšējā slēgšanas cena

33.62

Tehniskais rādītājs

By Trading Central

Pārliecība

Weak Bearish Evidence

Immunocore Holdings PLC ADR Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 16. sept. 17:03 UTC

Galvenie tirgus virzītāji

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

2025. g. 16. sept. 16:49 UTC

Galvenie tirgus virzītāji
Iegādes, apvienošanās, pārņemšana

GD Culture Shares Drop After Deal for Pallas Capital

2025. g. 16. sept. 16:11 UTC

Galvenie tirgus virzītāji

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

2025. g. 16. sept. 23:40 UTC

Tirgus saruna

Nikkei May Decline as Yen Strengthens -- Market Talk

2025. g. 16. sept. 23:34 UTC

Tirgus saruna

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

2025. g. 16. sept. 23:20 UTC

Tirgus saruna

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

2025. g. 16. sept. 21:10 UTC

Iegādes, apvienošanās, pārņemšana

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

2025. g. 16. sept. 20:51 UTC

Tirgus saruna

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

2025. g. 16. sept. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2025. g. 16. sept. 20:50 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2025. g. 16. sept. 20:25 UTC

Peļņas

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

2025. g. 16. sept. 20:24 UTC

Peļņas

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

2025. g. 16. sept. 19:19 UTC

Tirgus saruna

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

2025. g. 16. sept. 18:52 UTC

Tirgus saruna

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

2025. g. 16. sept. 18:44 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 16. sept. 18:44 UTC

Tirgus saruna

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

2025. g. 16. sept. 18:40 UTC

Iegādes, apvienošanās, pārņemšana

Details Emerge on U.S.-China TikTok Deal -- WSJ

2025. g. 16. sept. 18:38 UTC

Tirgus saruna

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

2025. g. 16. sept. 18:19 UTC

Tirgus saruna

Gold Settles at New High Ahead of Fed Decision -- Market Talk

2025. g. 16. sept. 18:01 UTC

Tirgus saruna

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

2025. g. 16. sept. 17:34 UTC

Tirgus saruna

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

2025. g. 16. sept. 16:53 UTC

Peļņas

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

2025. g. 16. sept. 16:20 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2025. g. 16. sept. 16:15 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Commodities Roundup: Market Talk

2025. g. 16. sept. 16:09 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Global Energy Roundup: Market Talk

2025. g. 16. sept. 16:09 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

2025. g. 16. sept. 15:35 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 16. sept. 15:35 UTC

Tirgus saruna

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

2025. g. 16. sept. 15:22 UTC

Tirgus saruna

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

2025. g. 16. sept. 15:21 UTC

Tirgus saruna

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Salīdzinājums

Cenas izmaiņa

Immunocore Holdings PLC ADR Prognoze

Cenas mērķis

By TipRanks

71.73% augšup

Prognoze 12 mēnešiem

Vidējais 59.11 USD  71.73%

Augstākais 100 USD

Zemākais 34 USD

Pamatojoties uz 9 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Immunocore Holdings PLC ADR — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

9 ratings

7

Pirkt

2

Turēt

0

Pārdot

Tehniskais rādītājs

By Trading Central

27.895 / 30.16Atbalsts un pretestība

Īstermiņā

Weak Bearish Evidence

Vidējā termiņā

Weak Bearish Evidence

Ilgtermiņā

Weak Bearish Evidence

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat